×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JSPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/5
10:45 am
jspr
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Medium
Report
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
1/24
05:09 am
jspr
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
1/13
10:58 am
jspr
Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Low
Report
Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
1/8
07:00 am
jspr
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
High
Report
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
1/7
04:30 pm
jspr
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
High
Report
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
12/2
07:00 am
jspr
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
High
Report
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
12/1
05:32 pm
jspr
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation [Yahoo! Finance]
High
Report
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation [Yahoo! Finance]
12/1
04:30 pm
jspr
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
High
Report
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
08:00 am
jspr
jasper therapeutics, inc. - class a
MISS
Report
-10.6%
jasper therapeutics, inc. - class a
8/13/2025
04:05 pm
jspr
jasper therapeutics, inc. - class a
MISS
Report
2.0%
jasper therapeutics, inc. - class a
5/12/2025
04:05 pm
jspr
jasper therapeutics, inc. - class a
MISS
Report
1.7%
jasper therapeutics, inc. - class a
2/27/2025
08:00 am
jspr
jasper therapeutics, inc. - class a
MISS
Report
-1.7%
jasper therapeutics, inc. - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/11
01:39 pm
jspr
Form SCHEDULE 13G Jasper Therapeutics, Filed by: MORGAN STANLEY
Low
Report
Form SCHEDULE 13G Jasper Therapeutics, Filed by: MORGAN STANLEY
2/10
04:01 pm
jspr
Form 4 Jasper Therapeutics, For: Feb 06 Filed by: Mahal Jeetinder Singh
Medium
Report
Form 4 Jasper Therapeutics, For: Feb 06 Filed by: Mahal Jeetinder Singh
1/26
03:29 pm
jspr
Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: ACORN BIOVENTURES, L.P.
Low
Report
Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: ACORN BIOVENTURES, L.P.
1/8
07:07 am
jspr
Form 8-K Jasper Therapeutics, For: Jan 08
High
Report
Form 8-K Jasper Therapeutics, For: Jan 08
1/7
04:35 pm
jspr
Form 8-K Jasper Therapeutics, For: Jan 02
High
Report
Form 8-K Jasper Therapeutics, For: Jan 02
1/5
07:31 pm
jspr
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: MARTELL RON
Medium
Report
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: MARTELL RON
1/5
07:30 pm
jspr
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: Mahal Jeetinder Singh
Medium
Report
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: Mahal Jeetinder Singh
1/5
07:30 pm
jspr
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: CROSS HERB
Medium
Report
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: CROSS HERB
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: